Jeffrey Jay and David Kroin‘s Great Point Partners reported the acquisition of 3.25 million common shares of Alimera Sciences Inc (NASDAQ:ALIM) which account for 5.12% of the company’s outstanding stock, via a recent 13G filing with the SEC. The acquisition represents a new addition to Great Point Partners’ portfolio.
Alimera Sciences is a pharmaceutical company that works on discovering and producing a variety of prescription ophthalmic pharmaceuticals. Since the beginning of the year, the company’s shares have lost 35.12%. For the second quarter of 2016, Alimera Sciences disclosed a loss per share of $0.17, topping the estimates of a loss per share of $0.19, and revenue of $9.56 million, also above analysts’ consensus estimate of $8.42 million. At the beginning of the month, Cowen and Company reiterated its ‘Market Perform’ rating on Alimera Sciences’ stock, with a price target of $2.00.
Investors that were bullish on Alimera Sciences (NASDAQ:ALIM) at the end of June included Thomas Ellis and Todd Hammer’s North Run Capital, with a position worth $4.31 million, and James E. Flynn’s Deerfield Management, with a $7.23 million position. An investor who initiated a new position in the company during the second quarter was Ben Levine, Andrew Manuel and Stefan Renold’s LMR Partners, which held a new $47,000 position in the stock at the end of the quarter.
You can access the original SEC filing by clicking here.
Ownership Summary Table
|Name||Sole Voting Power||Shared Voting Power||Sole Dispositive Power||Shared Dispositive Power||Aggregate Amount Owned Power||Percent of Class|
|Great Point Partners||0||3,245,000||0||3,245,000||3,245,000||5.12%|
|Dr. Jeffrey R. Jay, M.D||0||3,245,000||0||3,245,000||3,245,000||5.12%|
|Mr. David Kroin||0||3,245,000||0||3,245,000||3,245,000||5.12%|
Page 1 of 10 – SEC Filing
Under the Securities Exchange Act of 1934
|Alimera Sciences Inc.|
|(Name of Issuer)|
|(Title of Class of Securities)|
|August 11, 2016|
|(Date of Event which Requires Filing of this Statement)|
|Check the appropriate box to designate the rule pursuant to which this Schedule is filed:|
*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.